Download PDF
Semin Liver Dis 2014; 34(02): 162-171
DOI: 10.1055/s-0034-1375957
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Drug-Induced Liver Injury due to Cancer Chemotherapeutic Agents

Ranjeeta Bahirwani
1   Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
,
K. Rajender Reddy
1   Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
› Author Affiliations
Further Information

Publication History

Publication Date:
31 May 2014 (online)

    Permissions and Reprints

Abstract

Drug-induced liver injury (DILI) due to chemotherapeutic drugs is a significant cause of morbidity and mortality. Most cases of chemotherapy-induced hepatotoxicity are idiosyncratic and do not have a unique clinical or histological signature that is distinct from other agents that cause DILI. The major mechanisms underlying chemotherapy-related hepatotoxicity are based on the production of reactive metabolites generated by phase I oxidation reactions, immunological injury, or alterations in mitochondrial function. Underlying liver disease and hepatic involvement by tumor are important modifiers of liver injury, and reversibility is not universal after drug cessation. Chemotherapy can also exacerbate underlying liver disease, particularly hepatitis B, leading to worsening hepatic function. Diagnosing DILI due to chemotherapeutic agents is particularly challenging because competing etiologies, such as hepatotoxicity from other medications, opportunistic infections, radiation therapy, and pre-existing liver disease, are frequent.

Keywords

chemotherapy - drug-induced liver injury - hepatotoxicity - liver failure - hepatic dysfunction
 

  • References

  • 1 Lewis JH. Drug-induced liver disease. Med Clin North Am 2000; 84 (5) 1275-1311 , x
    CrossrefPubMedGoogle Scholar
  • 2 King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist 2001; 6 (2) 162-176
    CrossrefPubMedGoogle Scholar
  • 3 Larrey D. Drug-induced liver diseases. J Hepatol 2000; 32 (1, Suppl) 77-88
    PubMedGoogle Scholar
  • 4 National Cancer Institute. Cancer Therapy Evaluation Program. National Cancer Institute; 2005 . Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/newadverse_2006.pdf. Accessed October 30, 2013
    PubMedGoogle Scholar
  • 5 Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995; 333 (17) 1118-1127
    CrossrefPubMedGoogle Scholar
  • 6 Ceci G, Bella M, Melissari M, Gabrielli M, Bocchi P, Cocconi G. Fatal hepatic vascular toxicity of DTIC. Is it really a rare event?. Cancer 1988; 61 (10) 1988-1991
    CrossrefPubMedGoogle Scholar
  • 7 Asbury RF, Rosenthal SN, Descalzi ME, Ratcliffe RL, Arseneau JC. Hepatic veno-occlusive disease due to DTIC. Cancer 1980; 45 (10) 2670-2674
    CrossrefPubMedGoogle Scholar
  • 8 Le Couteur DG, Cogger VC, Markus AM , et al. Pseudocapillarization and associated energy limitation in the aged rat liver. Hepatology 2001; 33 (3) 537-543
    CrossrefPubMedGoogle Scholar
  • 9 Diehl AM. Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am J Physiol Gastrointest Liver Physiol 2002; 282 (1) G1-G5
    CrossrefPubMedGoogle Scholar
  • 10 Veteläinen R, van Vliet AK, van Gulik TM. Severe steatosis increases hepatocellular injury and impairs liver regeneration in a rat model of partial hepatectomy. Ann Surg 2007; 245 (1) 44-50
    CrossrefPubMedGoogle Scholar
  • 11 DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22 (1) 27-42
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Shulman HM, Fisher LB, Schoch HG, Henne KW, McDonald GB. Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 1994; 19 (5) 1171-1181
    CrossrefPubMedGoogle Scholar
  • 13 McDonald GB, Hinds MS, Fisher LD , et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118 (4) 255-267
    CrossrefPubMedGoogle Scholar
  • 14 Dix SP, Wingard JR, Mullins RE , et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17 (2) 225-230
    PubMedGoogle Scholar
  • 15 Marsh JC. Hepatic vascular toxicity of dacarbazine (DTIC): not a rare complication. Hepatology 1989; 9 (5) 790-792
    CrossrefPubMedGoogle Scholar
  • 16 Morgan M, Dodds A, Atkinson K, Szer J, Downs K, Biggs J. The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br J Haematol 1991; 77 (4) 529-534
    PubMedGoogle Scholar
  • 17 Gill RA, Onstad GR, Cardamone JM, Maneval DC, Sumner HW. Hepatic veno-occlusive disease caused by 6-thioguanine. Ann Intern Med 1982; 96 (1) 58-60
    CrossrefPubMedGoogle Scholar
  • 18 Stoneham S, Lennard L, Coen P, Lilleyman J, Saha V. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 123 (1) 100-102
    CrossrefPubMedGoogle Scholar
  • 19 Joensuu H, Söderström KO, Nikkanen V. Fatal necrosis of the liver during ABVD chemotherapy for Hodgkin's disease. A case report. Cancer 1986; 58 (7) 1437-1440
    CrossrefPubMedGoogle Scholar
  • 20 Houghton AN, Shafi N, Rickles FR. Acute hepatic vein thrombosis occurring during therapy for Hodgkin's disease: a case report. Cancer 1979; 44 (6) 2324-2329
    CrossrefPubMedGoogle Scholar
  • 21 Julie C, Lutz M, Aust D. Pathological analysis of hepatic injury after oxaliplatin-based neoadjuvant chemotherapy of colorectal cancer liver metastases: results of the EORTC Intergroup phase III study 40983. J Clin Oncol 2007; 25 : abstract 241
    PubMedGoogle Scholar
  • 22 Nakano H, Oussoultzoglou E, Rosso E , et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008; 247 (1) 118-124
    CrossrefPubMedGoogle Scholar
  • 23 Guha C, Kavanagh BD. Hepatic radiation toxicity: avoidance and amelioration. Semin Radiat Oncol 2011; 21 (4) 256-263
    CrossrefPubMedGoogle Scholar
  • 24 Reed Jr GB, Cox Jr AJ. The human liver after radiation injury. A form of veno-occlusive disease. Am J Pathol 1966; 48 (4) 597-611
    PubMedGoogle Scholar
  • 25 Hansen MM, Ranek L, Walbom S, Nissen NI. Fatal hepatitis following irradiation and vincristine. Acta Med Scand 1982; 212 (3) 171-174
    PubMedGoogle Scholar
  • 26 Kun LE, Camitta BM. Hepatopathy following irradiation and adriamycin. Cancer 1978; 42 (1) 81-84
    CrossrefPubMedGoogle Scholar
  • 27 Tefft M, Traggis D, Filler RM. Liver irradiation in children: acute changes with transient leukopenia and thrombocytopenia. Am J Roentgenol Radium Ther Nucl Med 1969; 106 (4) 750-765
    CrossrefPubMedGoogle Scholar
  • 28 Ishak KG, Zimmerman HJ. Morphologic spectrum of drug-induced hepatic disease. Gastroenterol Clin North Am 1995; 24 (4) 759-786
    PubMedGoogle Scholar
  • 29 Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11 (2) 272-276
    CrossrefPubMedGoogle Scholar
  • 30 Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26 (3) 664-669
    CrossrefPubMedGoogle Scholar
  • 31 Jakse G, Madersbacher H. [Stauffer's syndrome. Reversible hepatic dysfunction in renal cell carcinoma (author's transl)]. Wien Klin Wochenschr 1978; 90 (8) 268-270
    PubMedGoogle Scholar
  • 32 Chalasani N, Fontana RJ, Bonkovsky HL , et al; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135 (6) 1924-1934 , e1–e4
    CrossrefPubMedGoogle Scholar
  • 33 Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43 (2) 209-220
    CrossrefPubMedGoogle Scholar
  • 34 Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50 (3) 661-662
    CrossrefPubMedGoogle Scholar
  • 35 Vento S, Cainelli F, Mirandola F , et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996; 347 (8994) 92-93
    CrossrefPubMedGoogle Scholar
  • 36 de Pree C, Giostra E, Galetto A, Perrin L, Zulian GB. Hepatitis C virus acute exacerbation during chemotherapy and radiotherapy for oesophageal carcinoma. Ann Oncol 1994; 5 (9) 861-862
    PubMedGoogle Scholar
  • 37 Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 2012; 9 (3) 156-166
    CrossrefPubMedGoogle Scholar
  • 38 Frickhofen N, Wiesneth M, Jainta C , et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994; 83 (7) 1998-2004
    PubMedGoogle Scholar
  • 39 Strasser SI, Myerson D, Spurgeon CL , et al. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999; 29 (6) 1893-1899
    CrossrefPubMedGoogle Scholar
  • 40 Khan S, Ramwani JJ, O'Brien PJ. Hepatocyte toxicity of mechlorethamine and other alkylating anticancer drugs. Role of lipid peroxidation. Biochem Pharmacol 1992; 43 (9) 1963-1967
    CrossrefPubMedGoogle Scholar
  • 41 Brühl P, Günther U, Hoefer-Janker H, Hüls W, Scheef W, Vahlensieck W. Results obtained with fractionated ifosfamide massive-dose treatment in generalized malignant tumours. Int J Clin Pharmacol Biopharm 1976; 14 (1) 29-39
    PubMedGoogle Scholar
  • 42 Paschke R, Worst P, Brust J, Queisser W. [Hepatotoxicity with etoposide-ifosfamide combination therapy]. Onkologie 1988; 11 (6) 273-275
    CrossrefPubMedGoogle Scholar
  • 43 Falkson G, Hunt M, Borden EC, Hayes JA, Falkson CI, Smith TJ. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Invest New Drugs 1992; 10 (4) 337-343
    CrossrefPubMedGoogle Scholar
  • 44 Aubrey DA. Massive hepatic necrosis after cyclophosphamide. BMJ 1970; 3 (5722) 588
    PubMedGoogle Scholar
  • 45 Goldberg JW, Lidsky MD. Cyclophosphamide-associated hepatotoxicity. South Med J 1985; 78 (2) 222-223
    CrossrefPubMedGoogle Scholar
  • 46 Bacon AM, Rosenberg SA. Cyclophosphamide hepatotoxicity in a patient with systemic lupus erythematosus. Ann Intern Med 1982; 97 (1) 62-63
    CrossrefPubMedGoogle Scholar
  • 47 Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol 2006; 33 (1) 50-67
    PubMedGoogle Scholar
  • 48 Morris LE, Guthrie Jr TH. Busulfan-induced hepatitis. Am J Gastroenterol 1988; 83 (6) 682-683
    PubMedGoogle Scholar
  • 49 Lee JH, Choi SJ, Lee JH , et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 2005; 84 (5) 321-330
    CrossrefPubMedGoogle Scholar
  • 50 Giralt S, Thall PF, Khouri I , et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97 (3) 631-637
    CrossrefPubMedGoogle Scholar
  • 51 Rai KR, Peterson BL, Appelbaum FR , et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343 (24) 1750-1757
    CrossrefPubMedGoogle Scholar
  • 52 Romagnuolo J, Sadowski DC, Lalor E, Jewell L, Thomson AB. Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity. Can J Gastroenterol 1998; 12 (7) 479-483
    PubMedGoogle Scholar
  • 53 Small P, Lichter M. Probable azathioprine hepatotoxicity: a case report. Ann Allergy 1989; 62 (6) 518-520
    PubMedGoogle Scholar
  • 54 Barrowman JA, Kutty PK, Ra MU, Huang SN. Sclerosing hepatitis and azathioprine. Dig Dis Sci 1986; 31 (2) 221-222
    CrossrefPubMedGoogle Scholar
  • 55 Ménard DB, Gisselbrecht C, Marty M, Reyes F, Dhumeaux D. Antineoplastic agents and the liver. Gastroenterology 1980; 78 (1) 142-164
    PubMedGoogle Scholar
  • 56 Shorey J, Schenker S, Suki WN, Combes B. Hepatotoxicity of mercaptopurine. Arch Intern Med 1968; 122 (1) 54-58
    CrossrefPubMedGoogle Scholar
  • 57 McIlvanie SK, MacCarthy JD. Hepatitis in association with prolonged 6-mercaptopurine therapy. Blood 1959; 14 (1) 80-90
    PubMedGoogle Scholar
  • 58 Pizzuto J, Avilés A, Ramos E, Cervera J, Aguirre J. Cytosine arabinoside induced liver damage: histopathologic demonstration. Med Pediatr Oncol 1983; 11 (4) 287-290
    CrossrefPubMedGoogle Scholar
  • 59 George CB, Mansour RP, Redmond III J, Gandara DR. Hepatic dysfunction and jaundice following high-dose cytosine arabinoside. Cancer 1984; 54 (11) 2360-2362
    CrossrefPubMedGoogle Scholar
  • 60 Koren G, Beatty K, Seto A, Einarson TR, Lishner M. The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother 1992; 26 (3) 363-371
    PubMedGoogle Scholar
  • 61 Bateman JR, Pugh RP, Cassidy FR, Marshall GJ, Irwin LE. 5-fluorouracil given once weekly: comparison of intravenous and oral administration. Cancer 1971; 28 (4) 907-913
    CrossrefPubMedGoogle Scholar
  • 62 Aloia T, Sebagh M, Plasse M , et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24 (31) 4983-4990
    CrossrefPubMedGoogle Scholar
  • 63 Twelves C, Glynne-Jones R, Cassidy J , et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 1999; 5 (7) 1696-1702
    PubMedGoogle Scholar
  • 64 Doria Jr MI, Shepard KV, Levin B, Riddell RH. Liver pathology following hepatic arterial infusion chemotherapy. Hepatic toxicity with FUDR. Cancer 1986; 58 (4) 855-861
    CrossrefPubMedGoogle Scholar
  • 65 Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 206 (6) 685-693
    CrossrefPubMedGoogle Scholar
  • 66 Hohn D, Melnick J, Stagg R , et al. Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. J Clin Oncol 1985; 3 (1) 98-102
    PubMedGoogle Scholar
  • 67 Shepard KV, Levin B, Karl RC , et al. Therapy for metastatic colorectal cancer with hepatic artery infusion chemotherapy using a subcutaneous implanted pump. J Clin Oncol 1985; 3 (2) 161-169
    PubMedGoogle Scholar
  • 68 Krivoy N, Raz R, Carter A, Alroy G. Reversible hepatic veno-occlusive disease and 6-thioguanine. Ann Intern Med 1982; 96 (6 Pt 1): 788
    PubMedGoogle Scholar
  • 69 Larrey D, Fréneaux E, Berson A , et al. Peliosis hepatis induced by 6-thioguanine administration. Gut 1988; 29 (9) 1265-1269
    CrossrefPubMedGoogle Scholar
  • 70 Aapro MS, Martin C, Hatty S. Gemcitabine—a safety review. Anticancer Drugs 1998; 9 (3) 191-201
    CrossrefPubMedGoogle Scholar
  • 71 Teusink AC, Hall PD. Toxicities of gemcitabine in patients with severe hepatic dysfunction. Ann Pharmacother 2010; 44 (4) 750-754
    CrossrefPubMedGoogle Scholar
  • 72 Podurgiel BJ, McGill DB, Ludwig J, Taylor WF, Muller SA. Liver injury associated with methotrexate therapy for psoriasis. Mayo Clin Proc 1973; 48 (11) 787-792
    PubMedGoogle Scholar
  • 73 Evans WE, Pratt CB. Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther 1978; 23 (1) 68-72
    PubMedGoogle Scholar
  • 74 Avilés A, Herrera J, Ramos E, Ambriz R, Aguirre J, Pizzuto J. Hepatic injury during doxorubicin therapy. Arch Pathol Lab Med 1984; 108 (11) 912-913
    PubMedGoogle Scholar
  • 75 Johnson PJ, Dobbs N, Kalayci C , et al. Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters. Br J Cancer 1992; 65 (5) 751-755
    CrossrefPubMedGoogle Scholar
  • 76 Chan KK, Chlebowski RT, Tong M, Chen HS, Gross JF, Bateman JR. Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis. Cancer Res 1980; 40 (4) 1263-1268
    PubMedGoogle Scholar
  • 77 Erichsen C, Jönsson PE. Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma. J Surg Oncol 1984; 27 (4) 268-270
    CrossrefPubMedGoogle Scholar
  • 78 McClay E, Lusch CJ, Mastrangelo MJ. Allergy-induced hepatic toxicity associated with dacarbazine. Cancer Treat Rep 1987; 71 (2) 219-220
    PubMedGoogle Scholar
  • 79 Ludwig R, Weirich A, Abel U, Hofmann W, Graf N, Tournade MF. Hepatotoxicity in patients treated according to the nephroblastoma trial and study SIOP-9/GPOH. Med Pediatr Oncol 1999; 33 (5) 462s-469
    CrossrefPubMedGoogle Scholar
  • 80 Lazarus HM, Gottfried MR, Herzig RH , et al. Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantation. Cancer 1982; 49 (9) 1789-1795
    CrossrefPubMedGoogle Scholar
  • 81 Crooke ST, Bradner WT. Mitomycin C: a review. Cancer Treat Rev 1976; 3 (3) 121-139
    CrossrefPubMedGoogle Scholar
  • 82 Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000; 6 (4) 1255-1258
    PubMedGoogle Scholar
  • 83 Minami H, Kawada K, Sasaki Y , et al. Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Sci 2009; 100 (1) 144-149
    CrossrefPubMedGoogle Scholar
  • 84 National Institute of Health. DailyMed. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm. Accessed October 30, 2013
    PubMedGoogle Scholar
  • 85 Desai ZR, Van den Berg HW, Bridges JM, Shanks RG. Can severe vincristine neurotoxicity be prevented?. Cancer Chemother Pharmacol 1982; 8 (2) 211-214
    CrossrefPubMedGoogle Scholar
  • 86 Hohneker JA. A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 1994; 21 (5, Suppl 10) 42-46 , discussion 46–47
    PubMedGoogle Scholar
  • 87 Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, Shanks RG. The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol 1982; 8 (2) 215-219
    CrossrefPubMedGoogle Scholar
  • 88 Tran A, Housset C, Boboc B, Tourani JM, Carnot F, Berthelot P. Etoposide (VP 16-213) induced hepatitis. Report of three cases following standard-dose treatments. J Hepatol 1991; 12 (1) 36-39
    CrossrefPubMedGoogle Scholar
  • 89 Johnson DH, Greco FA, Wolff SN. Etoposide-induced hepatic injury: a potential complication of high-dose therapy. Cancer Treat Rep 1983; 67 (11) 1023-1024
    PubMedGoogle Scholar
  • 90 Stewart CF, Arbuck SG, Fleming RA, Evans WE. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J Clin Oncol 1990; 8 (11) 1874-1879
    PubMedGoogle Scholar
  • 91 Raymond E, Boige V, Faivre S , et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 2002; 20 (21) 4303-4312
    CrossrefPubMedGoogle Scholar
  • 92 Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200 (6) 845-853
    CrossrefPubMedGoogle Scholar
  • 93 Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat Rev 1994; 20 (1) 73-96
    CrossrefPubMedGoogle Scholar
  • 94 Hill JM, Loeb E, MacLellan A, Hill NO, Khan A, King JJ. Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases. Cancer Chemother Rep 1975; 59 (3) 647-659
    PubMedGoogle Scholar
  • 95 Hruban RH, Sternberg SS, Meyers P, Fleisher M, Menendez-Botet C, Boitnott JK. Fatal thrombocytopenia and liver failure associated with carboplatin therapy. Cancer Invest 1991; 9 (3) 263-268
    CrossrefPubMedGoogle Scholar
  • 96 Christian MC. Two toxicities associated with carboplatin use: A. gross hematuria B. hepatic veno-occlusive disease. Department of Health & Human Services Bulletin. Bethesda, MD: National Institutes of Health, National Cancer Institute; 1989
    Google Scholar
  • 97 Pollera CF, Ameglio F, Nardi M, Vitelli G, Marolla P. Cisplatin-induced hepatic toxicity. J Clin Oncol 1987; 5 (2) 318-319
    PubMedGoogle Scholar
  • 98 Fakih MG. 5-fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction. Oncology 2004; 67 (3-4) 222-224
    CrossrefPubMedGoogle Scholar
  • 99 Rubbia-Brandt L, Audard V, Sartoretti P , et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15 (3) 460-466
    Google Scholar
  • 100 Nordstrom BH, Fraeman KH, Luo W. Liver function test abnormalities in patients treated with small molecule tyrosine kinase inhibitors. Paper presented at: International Society for Pharmacoepidemiology Annual Meeting; August 19–22, 2010. ; Brighton, UK
    Google Scholar
  • 101 Chang J, Rand M, Blumenthal G. FDA evaluation of hepatotoxicity related to tyrosine kinase inhibitors. J Clin Oncol 2011; 29: 3106
    CrossrefPubMedGoogle Scholar
  • 102 Tujios S, Fontana RJ. Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol 2011; 8 (4) 202-211
    CrossrefPubMedGoogle Scholar
  • 103 Miller AA, Murry DJ, Owzar K , et al. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol 2007; 25 (21) 3055-3060
    CrossrefPubMedGoogle Scholar
  • 104 Liu W, Makrauer FL, Qamar AA, Jänne PA, Odze RD. Fulminant hepatic failure secondary to erlotinib. Clin Gastroenterol Hepatol 2007; 5 (8) 917-920
    CrossrefPubMedGoogle Scholar
  • 105 Pellegrinotti M, Fimognari FL, Franco A, Repetto L, Pastorelli R. Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer. Ann Pharmacother 2009; 43 (3) 542-545
    CrossrefPubMedGoogle Scholar
  • 106 Ho C, Davis J, Anderson F, Bebb G, Murray N. Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib. J Clin Oncol 2005; 23 (33) 8531-8533
    CrossrefPubMedGoogle Scholar
  • 107 Kikuchi S, Muroi K, Takahashi S , et al. Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes. Leuk Lymphoma 2004; 45 (11) 2349-2351
    CrossrefPubMedGoogle Scholar
  • 108 O'Brien SG, Guilhot F, Larson RA , et al; IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348 (11) 994-1004
    CrossrefPubMedGoogle Scholar
  • 109 Cross TJ, Bagot C, Portmann B, Wendon J, Gillett D. Imatinib mesylate as a cause of acute liver failure. Am J Hematol 2006; 81 (3) 189-192
    CrossrefPubMedGoogle Scholar
  • 110 Ferrero D, Pogliani EM, Rege-Cambrin G , et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica 2006; ; 91 (6, Suppl) ECR27
    PubMedGoogle Scholar
  • 111 Moy B, Rappold E, Williams L. Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib. J Clin Oncol 2009; 27: 1043
    PubMedGoogle Scholar
  • 112 Spraggs CF, Budde LR, Briley L. Hyperbilirubinemia in lapatinib treated patients is associated with Gilbert's syndrome UGT1A1 polymorphism. Cancer Res 2009; 69 (24) 69
    PubMedGoogle Scholar
  • 113 Spraggs CF, Budde LR, Briley LP , et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011; 29 (6) 667-673
    CrossrefPubMedGoogle Scholar
  • 114 Sternberg CN, Davis ID, Mardiak J , et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28 (6) 1061-1068
    CrossrefPubMedGoogle Scholar
  • 115 Xu CF, Reck BH, Xue Z , et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer 2010; 102 (9) 1371-1377
    CrossrefPubMedGoogle Scholar
  • 116 Shibata SI, Chung V, Synold TW , et al. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 2013; 19 (13) 3631-3639
    CrossrefPubMedGoogle Scholar
  • 117 Xu CF, Reck BH, Goodman VL , et al. Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J Hepatol 2011; 54 (6) 1237-1243
    PubMedGoogle Scholar
  • 118 Iclusig. [package insert]. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf . Accessed October 30, 2013
    PubMedGoogle Scholar
  • 119 Stivarga. [package insert]. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf Accessed October 30, 2013
    PubMedGoogle Scholar
  • 120 Sutent [package insert]. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021938s13s17s18lbl.pdf. Accessed October 30, 2013
    PubMedGoogle Scholar
  • 121 Fairfax BP, Pratap S, Roberts IS , et al. Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma. BMC Cancer 2012; 12: 590
    CrossrefPubMedGoogle Scholar
  • 122 Miller AA, Murry DJ, Owzar K , et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009; 27 (11) 1800-1805
    CrossrefPubMedGoogle Scholar
  • 123 Avastin [package insert]. South San Francisco, CA: Genentech; 2004
    Google Scholar
  • 124 Dent S, Oyan B, Honig A, Mano M, Howell S. HER2-targeted therapy in breast cancer: a systematic review of neoadjuvant trials. Cancer Treat Rev 2013; 39 (6) 622-631
    CrossrefPubMedGoogle Scholar
  • 125 Wolchok JD, Neyns B, Linette G , et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11 (2) 155-164
    CrossrefPubMedGoogle Scholar
  • 126 Robert C, Thomas L, Bondarenko I , et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364 (26) 2517-2526
    CrossrefPubMedGoogle Scholar
  • 127 Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30 (21) 2691-2697
    Google Scholar
  • 128 Pectasides D, Dafni U, Bafaloukos D , et al. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol 2009; 27 (6) 939-944
    CrossrefPubMedGoogle Scholar
  • 129 Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 1992; 102 (4 Pt 1) 1406-1408
    PubMedGoogle Scholar
  • 130 Nakagawa K, Miller FN, Sims DE, Lentsch AB, Miyazaki M, Edwards MJ. Mechanisms of interleukin-2-induced hepatic toxicity. Cancer Res 1996; 56 (3) 507-510
    PubMedGoogle Scholar
  • 131 Fisher B, Keenan AM, Garra BS , et al. Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients. J Clin Oncol 1989; 7 (12) 1852-1862
    PubMedGoogle Scholar